Cystic Fibrosis Lung
Cystic Fibrosis Lung - Related Videos
02:48
Preparation of Artificial Sputum Medium to Emulate Cystic Fibrosis Lung Sputum Ex Vivo
0 Views •
2025
Source: Vieira, J., et al. Design and Development of a Model to Study the Effect of Supplemental Oxygen on the Cystic Fibrosis Airway Microbiome. J. Vis. Exp. (2021).This video demonstrates the preparation of an artificial sputum medium that mimics the viscosity, nutrient composition, and pH of cystic fibrosis lung sputum. The resulting medium provides a physiologically relevant platform for ex vivo studies.
07:46
Use of Artificial Sputum Medium to Test Antibiotic Efficacy Against Pseudomonas aeruginosa in Conditions More Relevant to the Cystic Fibrosis Lung
0 Views •
Cited by 159 •
2012
Current diagnostic antimicrobial susceptibility testing relies on the planktonic growth of isolates in nutrient rich, aerobic conditions. Here, we employ an alternative artificial sputum medium to study antimicrobial susceptibility of Pseudomonas aeruginosa biofilms under both aerobic and microaerophilic conditions more representative of the cystic fibrosis lung.
01:23
Cystic Fibrosis: Pathogenesis
0 Views •
2024
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body. CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
14:56
Expression and Purification of the Cystic Fibrosis Transmembrane Conductance Regulator Protein in Saccharomyces cerevisiae
0 Views •
Cited by 19 •
2012
Attempts to express the cystic fibrosis transmembrane conductance regulator (CFTR) in Saccharomyces cerevisiae have, until now, yielded relatively low amounts of protein. This protocol and the associated reagents distributed via the Cystic Fibrosis Foundation should allow the preparation of milligram amounts of this 'difficult' eukaryotic membrane protein.
01:24
Cystic Fibrosis: Management
0 Views •
2024
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses. Sinus disease and chronic sinusitis...
FAQs
CFTR dysfunction changes more than mucus volume: reduced chloride and bicarbonate movement alters airway-surface liquid, leaving mucus dehydrated and viscous. That physical change makes mucociliary clearance less effective, so material remains in the airways instead of being removed. The resulting environment helps explain why epithelial ion transport is a central target in cystic fibrosis lung research.
When mucus is not effectively cleared, bacteria can persist within the airways and continue stimulating inflammation. This creates a self-reinforcing relationship between infection and immune activity, in which inflammation contributes to tissue injury while airway damage further compromises respiratory function. Studying this sequence helps explain progressive structural injury and declining lung function.
CFTR-modulating treatments are designed to restore epithelial ion transport, addressing an underlying transport defect that affects airway conditions. Antimicrobial therapies instead target infection, whereas anti-inflammatory therapies address the host inflammatory response. Comparing these approaches helps distinguish interventions aimed at the initiating defect from those directed at downstream consequences in the cystic fibrosis lung.
The cystic fibrosis lung provides a setting in which altered airway conditions, bacterial persistence, and immune responses can be considered together. Researchers can examine how defective epithelial ion transport and retained mucus influence the relationship between bacteria and host defenses, while also assessing how that interaction contributes to chronic inflammation and respiratory injury.
Treatment assessment can consider whether an intervention improves respiratory outcomes, including lung function and airway structure. Studies may also relate those outcomes to the processes driving disease, such as persistent infection, chronic inflammation, or abnormal epithelial ion transport. This broader evaluation distinguishes improvement in respiratory performance from effects on the underlying airway environment.
Persistent infection and immune-mediated tissue injury are connected components of the disease process rather than isolated findings. Bacterial persistence can stimulate chronic inflammation, while inflammation contributes to progressive airway damage and reduced lung function. Considering both processes supports a more complete evaluation of antimicrobial, anti-inflammatory, and CFTR-modulating treatments in immunology and infection research.